Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Options
Curis put volume heavy and directionally bearish » 13:15
05/14/21
05/14
13:15
05/14/21
13:15
CRIS

Curis

$13.68 /

+0.64 (+4.91%)

Bearish flow noted in…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
CRIS Curis
$13.68 /

+0.64 (+4.91%)

CRIS Curis
$13.68 /

+0.64 (+4.91%)

05/13/21 B. Riley
Curis price target raised to $22 from $19 at B. Riley
05/13/21 Cantor Fitzgerald
Curis price target raised to $24 from $15 at Cantor Fitzgerald
05/12/21 Cantor Fitzgerald
Rigel rallying on Curis IRAK4 program data, says Cantor Fitzgerald
05/12/21 Cantor Fitzgerald
Initial look from Curis EHA updates 'very positive,' says Cantor Fitzgerald
CRIS Curis
$13.68 /

+0.64 (+4.91%)

  • 09
    Dec
CRIS Curis
$13.68 /

+0.64 (+4.91%)

CRIS Curis
$13.68 /

+0.64 (+4.91%)

Hot Stocks
Veracyte announces data showing Percepta Genomic Atlas detects gene alterations » 12:46
05/14/21
05/14
12:46
05/14/21
12:46
VCYT

Veracyte

$36.81 /

+1.7 (+4.84%)

Veracyte announced new…

Veracyte announced new data demonstrating the ability of the Percepta Genomic Atlas to detect alterations that may inform lung cancer treatment decisions for patients from the same small biopsy that was used for diagnosis. Study findings presented today at the American Thoracic Society 2021 International Conference show that the test accurately detects known lung-cancer gene variants using small biopsy samples, which may help guide treatment with targeted therapies. For the analyses presented at the ATS Conference, researchers evaluated the feasibility of detecting National Comprehensive Cancer Network-recommended gene alterations with the Percepta Genomic Atlas, using samples from 25 patients obtained during initial bronchoscopy procedures. Results show that the in-development test accurately detected the gene variants in these samples with over 95% concordance to a reference next-generation sequencing assay.

ShowHide Related Items >><<
VCYT Veracyte
$36.81 /

+1.7 (+4.84%)

VCYT Veracyte
$36.81 /

+1.7 (+4.84%)

05/11/21 Needham
Veracyte price target lowered to $54 from $88 at Needham
05/11/21 SVB Leerink
Veracyte price target lowered to $65 from $75 at SVB Leerink
04/27/21 SVB Leerink
Veracyte price target lowered to $75 from $85 at SVB Leerink
02/18/21 Needham
Veracyte assumed with a Buy at Needham
VCYT Veracyte
$36.81 /

+1.7 (+4.84%)

  • 05
    Feb
  • 05
    Aug
Conference/Events
NextCure management to meet virtually with Roth Capital » 10:55
05/14/21
05/14
10:55
05/14/21
10:55
NXTC

NextCure

$8.04 /

+ (+0.00%)

Virtual Meetings to be…

Virtual Meetings to be held May 17-18 hosted by Roth Capital.

ShowHide Related Items >><<
NXTC NextCure
$8.04 /

+ (+0.00%)

NXTC NextCure
$8.04 /

+ (+0.00%)

03/05/21 Truist
NextCure upgraded to Buy from Hold at Truist
03/05/21 Truist
NextCure upgraded to Buy from Hold at Truist
03/04/21 Piper Sandler
NextCure price target lowered to $26 from $32 at Piper Sandler
01/15/21 BofA
NextCure downgraded to Underperform on low conviction in NC318 at BofA
NXTC NextCure
$8.04 /

+ (+0.00%)

Recommendations
TCR2 Therapeutics price target lowered to $45 from $57 at Wedbush » 07:27
05/14/21
05/14
07:27
05/14/21
07:27
TCRR

TCR2 Therapeutics

$19.05 /

-0.31 (-1.60%)

Wedbush analyst David…

Wedbush analyst David Nierengarten lowered the firm's price target on TCR2 Therapeutics to $45 from $57 and keeps an Outperform rating on the shares. The company reaffirmed that it is on track todetermine a recommended Phase 2 dose of gavo-cel for treatment-refractory mesothelin-expressing solid tumors and expects to initiate its Phase 1/2 expansion trial this year, Nierengarten tells investors in a research note. The analyst expects continued updates from treated patients over the rest of the year.

ShowHide Related Items >><<
TCRR TCR2 Therapeutics
$19.05 /

-0.31 (-1.60%)

TCRR TCR2 Therapeutics
$19.05 /

-0.31 (-1.60%)

03/12/21 Mizuho
TCR2 Therapeutics price target lowered to $51 from $58 at Mizuho
03/11/21 BMO Capital
TCR2 Therapeutics price target lowered to $56 from $65 at BMO Capital
03/11/21 Piper Sandler
TCR2 Therapeutics price target raised to $55 from $45 at Piper Sandler
12/22/20 Mizuho
Autolus, Arcus among top 2021 oncology picks at Mizuho
TCRR TCR2 Therapeutics
$19.05 /

-0.31 (-1.60%)

  • 20
    Jan
  • 29
    Jul
Earnings
Cullinan reports Q1 EPS 0c, consensus 6c » 06:34
05/14/21
05/14
06:34
05/14/21
06:34
CGEM

Cullinan

$27.90 /

-2.38 (-7.86%)

Reports Q1 revenue…

Reports Q1 revenue $18.94M, consensus $19M. Reports cash, cash equivalents and investments of $473.0M as of March 31 post completion of Initial Public Offering in early January. "I am pleased with the progress we have made across our portfolio and our organization thus far in 2021," stated Owen Hughes, CEO of Cullinan. "Our recently completed Series C financing and Initial Public Offering will support continued development and expansion of our diverse pipeline. In addition, we look forward to sharing both clinical and preclinical updates throughout the year, including a poster presentation with updated clinical data for Cullinan Pearl at ASCO in June and updated preclinical data on Cullinan Amber at the Next-Gen Cytokine Therapeutics Summit in the Q3."

ShowHide Related Items >><<
CGEM Cullinan
$27.90 /

-2.38 (-7.86%)

CGEM Cullinan
$27.90 /

-2.38 (-7.86%)

04/27/21
Fly Intel: Top five analyst upgrades
04/27/21 Morgan Stanley
Cullinan upgraded to Overweight ahead of CLN-081 data at Morgan Stanley
04/27/21 Morgan Stanley
Cullinan upgraded to Overweight from Equal Weight at Morgan Stanley
02/02/21 SVB Leerink
SVB Leerink bullish on Cullinan, initiates with an Outperform
  • 08
    Jan
CGEM Cullinan
$27.90 /

-2.38 (-7.86%)

Yesterday
Earnings
Bolt Biotherapeutics reports Q1 EPS ($1.14), consensus (60c) » 16:39
05/13/21
05/13
16:39
05/13/21
16:39
BOLT

Bolt Biotherapeutics

$18.24 /

-1.15 (-5.93%)

Cash, cash equivalents,…

Cash, cash equivalents, and marketable securities were $302.9 million as of March 31, 2021, which is expected to fund operations into 2023 - Bolt is well positioned to continue to drive growth across the company and advance the pipeline through key milestones, with cash to fund operations into 2023. "Our successful IPO in the first quarter of 2021 places us in a position of strength to deliver on value-creating milestones in 2021 and 2022. We continue to advance our Phase 1/2 trial for our lead candidate, BDC-1001, for the treatment of patients with HER2-expressing solid tumors. We look forward to completing the monotherapy dose escalation and initiating the monotherapy Phase 2 dose expansion cohorts as well as the evaluation of combining BDC-1001 with an anti-PD-1 antibody later in 2021," said Randall C. Schatzman, Ph.D., Chief Executive Officer of Bolt. "Beyond BDC-1001, we continue to advance our pipeline and are on track to initiate clinical trials for CEA-targeted ISAC BDC-2034 in 2022 and we expect to designate our third clinical candidate later this year."

ShowHide Related Items >><<
BOLT Bolt Biotherapeutics
$18.24 /

-1.15 (-5.93%)

BOLT Bolt Biotherapeutics
$18.24 /

-1.15 (-5.93%)

03/02/21
Fly Intel: Top five analyst initiations
03/02/21 SVB Leerink
Bolt Biotherapeutics initiated with an Outperform at SVB Leerink
03/02/21 Morgan Stanley
Bolt Biotherapeutics initiated with an Overweight at Morgan Stanley
03/02/21 Stifel
Bolt Biotherapeutics initiated with a Buy at Stifel
BOLT Bolt Biotherapeutics
$18.24 /

-1.15 (-5.93%)

  • 05
    Feb
BOLT Bolt Biotherapeutics
$18.24 /

-1.15 (-5.93%)

Initiation
Verrica Pharmaceuticals initiated with an Outperform at RBC Capital » 16:20
05/13/21
05/13
16:20
05/13/21
16:20
VRCA

Verrica Pharmaceuticals

$11.67 /

+0.11 (+0.95%)

RBC Capital analyst…

RBC Capital analyst Daniel Busby initiated coverage of Verrica Pharmaceuticals with an Outperform rating and $19 price target. Verrica's lead product, YCANTH, has the potential to supplant compounded cantharidin in "several important dermatology markets," argues Busby. He forecasts combined peak sales for YCANTH of about $500M across three indications and sees an "attractive entry point" ahead of the company's upcoming PDUFA date on June 23, Busby added.

ShowHide Related Items >><<
VRCA Verrica Pharmaceuticals
$11.67 /

+0.11 (+0.95%)

VRCA Verrica Pharmaceuticals
$11.67 /

+0.11 (+0.95%)

03/08/21 H.C. Wainwright
Verrica Pharmaceuticals price target raised to $24 from $21 at H.C. Wainwright
12/24/20 Cowen
Verrica approval for molluscum likely in Q3 of 2021, says Cowen
12/24/20 H.C. Wainwright
Verrica Pharmaceuticals price target raised to $21 from $18 at H.C. Wainwright
07/15/20 BofA
Verrica Pharmaceuticals downgraded to Neutral from Buy at BofA
VRCA Verrica Pharmaceuticals
$11.67 /

+0.11 (+0.95%)

  • 23
    Mar
VRCA Verrica Pharmaceuticals
$11.67 /

+0.11 (+0.95%)

VRCA Verrica Pharmaceuticals
$11.67 /

+0.11 (+0.95%)

Conference/Events
Cantor Fitzgerald biotech analysts to hold analyst/industry conference call » 12:25
05/13/21
05/13
12:25
05/13/21
12:25
CRIS

Curis

$13.74 /

-2.53 (-15.55%)

Biotechnology Analysts,…

Biotechnology Analysts, along with Dr. Matsui, Deputy Director of Livestrong Cancer Institute, discuss Curis CA-4948 for treatment of AML and MDS in IRAK-4 Biology on an Analyst/industry Conference Call to be held on May 13 at 1 pm.

ShowHide Related Items >><<
CRIS Curis
$13.74 /

-2.53 (-15.55%)

CRIS Curis
$13.74 /

-2.53 (-15.55%)

05/13/21 B. Riley
Curis price target raised to $22 from $19 at B. Riley
05/13/21 Cantor Fitzgerald
Curis price target raised to $24 from $15 at Cantor Fitzgerald
05/12/21 Cantor Fitzgerald
Rigel rallying on Curis IRAK4 program data, says Cantor Fitzgerald
05/12/21 Cantor Fitzgerald
Initial look from Curis EHA updates 'very positive,' says Cantor Fitzgerald
CRIS Curis
$13.74 /

-2.53 (-15.55%)

  • 09
    Dec
CRIS Curis
$13.74 /

-2.53 (-15.55%)

CRIS Curis
$13.74 /

-2.53 (-15.55%)

Conference/Events
Cantor Fitzgerald biotech analysts to hold analyst/industry conference call » 10:13
05/13/21
05/13
10:13
05/13/21
10:13
CRIS

Curis

$13.90 /

-2.37 (-14.57%)

Biotechnology Analysts,…

Biotechnology Analysts, along with Dr. Matsui, Deputy Director of Livestrong Cancer Institute, discuss Curis CA-4948 for treatment of AML and MDS in IRAK-4 Biology on an Analyst/industry Conference Call to be held on May 13 at 1 pm.

ShowHide Related Items >><<
CRIS Curis
$13.90 /

-2.37 (-14.57%)

CRIS Curis
$13.90 /

-2.37 (-14.57%)

05/13/21 B. Riley
Curis price target raised to $22 from $19 at B. Riley
05/13/21 Cantor Fitzgerald
Curis price target raised to $24 from $15 at Cantor Fitzgerald
05/12/21 Cantor Fitzgerald
Rigel rallying on Curis IRAK4 program data, says Cantor Fitzgerald
05/12/21 Cantor Fitzgerald
Initial look from Curis EHA updates 'very positive,' says Cantor Fitzgerald
CRIS Curis
$13.90 /

-2.37 (-14.57%)

  • 09
    Dec
CRIS Curis
$13.90 /

-2.37 (-14.57%)

CRIS Curis
$13.90 /

-2.37 (-14.57%)

Hot Stocks
Freeline Therapeutics Holdings Plc (ADS) trading resumes  10:05
05/13/21
05/13
10:05
05/13/21
10:05
FRLN

Freeline

$8.71 /

-0.69 (-7.34%)

 
ShowHide Related Items >><<
FRLN Freeline
$8.71 /

-0.69 (-7.34%)

FRLN Freeline
$8.71 /

-0.69 (-7.34%)

05/06/21
Fly Intel: Top five analyst initiations
05/06/21 Guggenheim
Freeline initiated with a Buy at Guggenheim
03/22/21 Mizuho
Freeline initiated with a Buy at Mizuho
03/01/21 Stifel
Freeline initiated with a Buy at Stifel
  • 07
    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.